ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,020
+1,280 (8.68%)
Apr 1, 2026, 3:30 PM KST
Market Cap175.65B -14.9%
Revenue (ttm)5.26B -44.9%
Net Income-16.11B
EPS-1,482.00
Shares Out10.96M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume177,325
Average Volume136,183
Open15,350
Previous Close14,740
Day's Range15,090 - 16,200
52-Week Range10,000 - 20,950
Betan/a
RSI52.12
Earnings Daten/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2025, ENCell's revenue was 5.26 billion, a decrease of -27.06% compared to the previous year's 7.21 billion. Losses were -16.11 billion, 5.90% more than in 2024.

Financial Statements